Cue Biopharma (CUE) Receivables (2019 - 2025)
Cue Biopharma (CUE) posted Receivables of $5.5 million for Q4 2025, up 1333.07% sequentially from $387000.0 in Q3 2025, and up 486.88% YoY from $945000.0 in Q4 2024.
Cue Biopharma (CUE) Receivables (2019 - 2025) Analysis & Trends
Cue Biopharma has reported Receivables for 7 years, with the latest figure at $5.5 million in Q4 2025.
- Quarterly Receivables rose 486.88% year-over-year to $5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.5 million (up 486.88% YoY) and the FY2025 annual result came in at $5.5 million, up 486.88% from the prior year.
- Receivables advanced to $5.5 million in Q4 2025 per CUE's latest filing, from $387000.0 in the prior quarter.
- Over five years, Receivables peaked at $5.5 million in Q4 2025 and troughed at $57000.0 in Q4 2022.
- A 5-year average of $1.5 million and a median of $1.1 million in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2023: Receivables tumbled 98.19% in 2022, then surged 2878.95% in 2023.
- Over 5 years, Receivables stood at $3.1 million in 2021, then tumbled by 98.19% to $57000.0 in 2022, then soared by 2878.95% to $1.7 million in 2023, then plunged by 44.35% to $945000.0 in 2024, then jumped by 486.88% to $5.5 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $5.5 million, $387000.0, and $532000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.55 Mn |
| Sep 30, 2025 | 387,000.00 |
| Jun 30, 2025 | 532,000.00 |
| Dec 31, 2024 | 945,000.00 |
| Sep 30, 2024 | 3.15 Mn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | 1.40 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 1.66 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 196,000.00 |
| Dec 31, 2022 | 57,000.00 |
| Sep 30, 2022 | 796,000.00 |
| Jun 30, 2022 | 736,000.00 |
| Mar 31, 2022 | 925,000.00 |
| Dec 31, 2021 | 3.14 Mn |
| Sep 30, 2021 | 771,000.00 |
| Jun 30, 2021 | 1.90 Mn |
| Mar 31, 2021 | 1.41 Mn |
| Dec 31, 2020 | 1.42 Mn |